

UPCM⁺ PHARMACOLOGY

REFERENCES

UPCM⁺ Pharmacology covers Basic Principles of Pharmacodynamics and Pharmacokinetics. This is composed of **seven (7) modules and around thirty (30) hours of coursework** designed to introduce and facilitate understanding of important concepts in Pharmacology relevant to students of both medical and paramedical fields. The principles of how drug works and is handled by the body are presented using common drugs that students can also familiarize with. The course is composed of the following:

OVERVIEW

This module presents a brief overview of the objectives, scope, mode of teaching and evaluation of this course. It will also touch on definitions of pharmacology, its branches or fields, and the history of Pharmacology in the Philippines with special focus on the UP College of Medicine.

MODULE 1 INTRODUCTION TO PHARMACOLOGY

This module discusses basic concepts about drugs, including different ways of naming, classifying, grouping, and administering them.

MODULE 2 MECHANISMS OF DRUG ACTION

This module discusses the mechanisms of drug actions including both receptor-mediated and non-receptor mediated drug actions. Specific prototype drugs will be given per mechanism of drug action. Novel drug mechanisms will be discussed briefly in the end.

MODULE 3 PHARMACODYNAMICS

This module talks about receptor-mediated action and effects of drugs on the body. This encompasses drug-receptor interaction, graded and quantal dose-response relationships, and important drug parameters derived from dose-response curves.

MODULE 4 PHARMACOKINETICS

This module introduces the concept of pharmacokinetics, on how a drug reaches its target. This encompasses how a drug is absorbed, distributed, metabolized and excreted.

MODULE 5 PHARMACOGENETICS

This short module discusses how genetics can alter the effects and disposition of drugs, and thus, response of the individual to drugs.

MODULE 6 DRUG TOXICITY AND ADVERSE DRUG REACTION

This module describes adverse drug reaction and drug interaction, including definitions, classification, types, and mechanisms of action leading to toxicity or harmful effects.

MODULE 7 DRUG DISCOVERY AND DEVELOPMENT

Drug discovery is a complex process, involving the fields of pharmacology, medicine and biotechnology, in order to identify compounds with the potential to become therapeutic agents.

WRAP-UP

Summarizes what you have learned from the course and its relevance in the pharmacologic treatment of disease.

The **references for the videos and script** used in UPCM⁺ Pharmacology are as follows:

MAJOR REFERENCES:

1. Katzung BG et al. eds. *Basic and Clinical Pharmacology, 15e*. McGraw-Hill; 2021.
2. Katzung BG, editor, *Basic and Clinical Pharmacology 14th edition*, 2018
3. Trevor AJ, Katzung BG, Masters SB (eds). *Katzung and Trevor's Pharmacology Examination and Board Review, 12th edition*.
4. Rang HP, Dale MM, Ritter JM, et al. (eds). Panganiban LR et al (adapting eds.) *Pharmacology, Philippine edition*. Elsevier, Singapore, 2015.
5. Ritter J., Flower R., Henderson, G. Loke YK, Mac Ewan D, and Rang, H., 2018. *Rang and Dale's pharmacology (9th edition)*. [Edinburgh etc.]: Elsevier, Churchill Livingstone.

ADDITIONAL REFERENCES:

MODULE 4 PHARMACOKINETICS

Rowland M & Tozer TN. *Clinical Pharmacokinetics. Concepts and Applications*. 3rd edition. Lippincott, Williams and Wilkins, 1995.

MODULE 5 PHARMACOGENETICS

1. Sy RG, Nevado JB, Llanes EJB, et al. The *Klotho* Variant rs 36217263 Is Associated with Poor Response to Cardioselective Beta-blocker Therapy Among Filipinos. *Clin Pharmacol Ther* 2020; 107(1): 221-226.
2. Ona DID, Nevado JB, Ramos JDA, et al. Variant rs6596140 of *Follistatin-like 4* Gene (*FSTL4*) May Be Associated with Poor Response to Angiotensin Receptor Blockers (ARBs) among Filipinos. *Phil J Sci*, 2021;150 (4):703-21.
3. Orrico, KB. Basic Concepts in Genetics and Pharmacogenomics for Pharmacists. *Drug Targets Insights*. 2019; 13:1-7 Basic Concepts in Genetics and Pharmacogenomics for Pharmacists
4. Baniyadi S. Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System, *Current Drug Metabolism* 2020; 21(9) .
<https://dx.doi.org/10.2174/1389200221999200820164038>
5. Shabbir A. [Genomics, Proteomics & Bioinformatics Volume 14, Issue 5](#), October 2016, Pages 298-313. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
6. Xie, H. G., & Frueh, F. W. (2005). Pharmacogenomics Steps Toward Personalized Medicine. *Personalized Medicine*, 2(4), 325–337.
<https://doi.org/10.2217/17410541.2.4.325>
7. Liao, J.K. 2007. Safety and efficacy of statins in Asians. *The American journal of cardiology*, 99(3), pp.410-414.c

MODULE 6 DRUG TOXICITY AND ADVERSE DRUG REACTION

1. Aagaard, L., Strandell, J., Melskens, L., Petersen, P.S.G., and Hansen, E.B. (2012). Global Patterns of Adverse Drug Reactions Over a Decade. *Drug Safety*; 35(12): 1171-1182)
2. Edwards IR, Aronson JK. (2000). Adverse drug reactions: definitions, diagnosis, and management. *Lancet*; 356:1255-59
3. Aronson, J.K., and Grahame-Smith, D.G. (1981). Adverse drug interactions. *British Medical Journal*; 282: 288-291.
4. Griffin JP, D'Arcy PF, Speirs CJ: *A Manual of Adverse Drug Interactions*, 4th edition. Butterworth and Company, Ltd., 1988.
5. World Health Organization (2002). *Safety of Medicines A guide to detecting and reporting adverse drug reaction*

MODULE 7 DRUG DISCOVERY AND DEVELOPMENT

1. Richard C. Mohs, Nigel H. Greig, *Drug discovery and development: Role of basic biological research, Alzheimer's & Dementia: Translational Research & Clinical Interventions* 2017;3 (4): 51-657, ISSN 2352-8737, <https://doi.org/10.1016/j.trci.2017.10.005>.
2. Amol B Deore, Jayprabha R Dhumane and Rushikesh Wagh et al. The Stages of Drug Discovery and Development Process. *Asian J Pharm Res Dev*. 2019. Vol. 7(6):62-67. DOI: 10.22270/ajprd.v7i6.616
3. Blass, B. E. (2014). Drug Discovery and Development: An Overview of Modern Methods and Principles. *Basic Principles of Drug Discovery and Development*, 1-34.
4. Brodniewicz, Teresa & Gryniewicz, Grzegorz. (2010). Preclinical Drug Development. *Acta poloniae pharmaceutica*. 67. 578-85
5. Chopra B, Dhingra AK. Natural products: A lead for drug discovery and development. *Phytother Res*. 2021 Sep;35(9):4660-4702. doi: 10.1002/ptr.7099. Epub 2021 Apr 13. PMID: 33847440.
6. Cortes-Maramba NP. Medicinal Plants in the Philippines. In Tomlinson TR, Olayiwola A, editors. *Medicinal Plants their role in health and biodiversity*. 1998. University of Pennsylvania Press, Philadelphia, pp 169-176.
7. Dayrit FM, Lagurin LG, 1994. Identification of 4 iridoids in the pharmacologic active fraction of *Vitex negundo* L. *Philippine Journal of Science*; 123 (4): 293-304
8. De Leon D, Cortes-Maramba NP, et al, 1996. *Blumea balsamifera*, L. (Sambong) for the treatment of Urinary Tract Stones: A Randomized placebo controlled study Phase III Clinical Trial. Sambong Technology Transfer Document, NIRPROMP and the Philippine Council for Health Research and Development.
9. Deore AB, Dhumane JR, Wagh R, Sonawane R. The stages of drug discovery and development process. *Asian Journal of Pharmaceutical Research and Development*. 2019 Dec 15;7(6):62-7.

10. Gilbert B, Alves LF, 2003. Synergy in plant medicines. *Current Medicinal Chemistry*; 10: 13-20.
11. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. *British journal of pharmacology*. 2011 Mar;162(6):1239-49.
12. Kiriiri, G.K., Njogu, P.M. & Mwangi, A.N. Exploring different approaches to improve the success of drug discovery and development projects: a review. *Futur J Pharm Sci*. 2020; 6 (27).
13. Maramba NPC et al, 1989. Clinical Trial of lagundi tablet as an antitussive. Lagundi (Vitex negundo L.) Monograph. PCHRD Technical report series no. 6. Pp 37-66.
14. Patel J, Shah S, Deshpande S, Shah G, 2009. Evaluation of the antiasthmatic activity of leaves of Vitex negundo. *Asian Journal of Pharmaceutical and Clinical Research*; 2(1): 81-86.
15. Purificacion J, 1994. Extended Phase III Open clinical trial of *Blumea balsamifera*, L. (Sambong) tablet in the treatment of urinary tract stone. *The Filipino Physician*; 33 (1): 17-25.
16. Rang HP, Dale MM, Ritter Flower RJ, Henderson with Philippine Adapting Editors (2015) "Herbal Medicine," in *Rang and Dale's Pharmacology Philippine Edition*. Singapore: Elsevier Churchill Livingstone.
17. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine 2000.
18. Willcox ML, Graz B, Falquet J, Diakite C, Giani S, Diallo D. A "reverse pharmacology" approach for developing an anti-malarial phytomedicine. *Malaria Journal*. 2011 Dec;10(1):1-0.